Compare Lennar Corporation (LEN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Mesoblast Limited — how do they compare? Lennar Corporation trades at $81.88 (market cap $19.92B), while Mesoblast Limited trades at $16.34 (market cap $2.17B). The key difference: Lennar Corporation is far larger — about 9.2× Mesoblast Limited's market cap, and Lennar Corporation pays a 2.41% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| LEN | MESO | |
|---|---|---|
Market Cap | $19.92B | $2.17B |
Sector | Consumer Cyclical | Technology |
52-Week High | $142.40 | $20.96 |
52-Week Low | $82.30 | $12.88 |
Enterprise Value | $23.80B | $2.17B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
